^
    16d
    SNAPI: Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Jan 2025 --> Jan 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    Opdivo (nivolumab) • sitravatinib (MGCD516)
    1m
    Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study. (PubMed, Future Oncol)
    Most treatment-emergent adverse events were mild-to-moderate in severity. The study closed before the planned number of patients were enrolled in all cohorts. Sitravatinib had a manageable safety profile with modest signals of clinical activity in patients with molecularly selected solid tumors.Clinical trial registration: www.clinicaltrials.gov identifier is NCT02219711.
    P1 data • Journal
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • AXL (AXL Receptor Tyrosine Kinase) • KDR (Kinase insert domain receptor) • DDR2 (Discoidin domain receptor 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MET mutation • RET rearrangement • CBL mutation
    |
    sitravatinib (MGCD516)
    3ms
    Screening of differential gene expression patterns through survival analysis for diagnosis, prognosis and therapies of clear cell renal cell carcinoma. (PubMed, PLoS One)
    Then we detected 10 repurposable drug molecules (Irinotecan, Imatinib, Telaglenastat, Olaparib, RG-4733, Sorafenib, Sitravatinib, Cabozantinib, Abemaciclib, and Dovitinib.) by molecular docking with KGs-mediated receptor proteins. Their ADME/T analysis and cross-validation with the independent receptors, also supported their potent against ccRCC. Therefore, these outputs might be useful inputs/resources to the wet-lab researchers and clinicians for considering an effective treatment strategy against ccRCC.
    Journal • PARP Biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • SERPINA5 (Serpin Family A Member 5)
    |
    Lynparza (olaparib) • sorafenib • imatinib • Verzenio (abemaciclib) • Cabometyx (cabozantinib tablet) • irinotecan • dovitinib (TKI258) • telaglenastat (CB-839) • sitravatinib (MGCD516) • RG4733
    4ms
    SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer. (PubMed, Cancer Immunol Immunother)
    Sitravatinib with/without tislelizumab was generally well tolerated and showed preliminary antitumor activity in patients with advanced HCC and GC/GEJC.
    P1/2 data • Journal • Metastases
    |
    AXL (AXL Receptor Tyrosine Kinase) • KDR (Kinase insert domain receptor)
    |
    Tevimbra (tislelizumab-jsgr) • sitravatinib (MGCD516)
    4ms
    Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer. (PubMed, Invest New Drugs)
    Strong indicators for clinical activity were not seen in patients with CRPC and bone metastases. Clinical trial registration:ClinicalTrials.gov NCT02219711.
    P1 data • Journal • Metastases
    |
    AXL (AXL Receptor Tyrosine Kinase) • KDR (Kinase insert domain receptor)
    |
    sitravatinib (MGCD516)
    5ms
    AAAQ8661: Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas (clinicaltrials.gov)
    P2, N=29, Completed, Columbia University | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    sitravatinib (MGCD516)
    6ms
    Targeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibition. (PubMed, Cancers (Basel))
    Given the roles of the TAM receptors in promoting the creation of an immunosuppressive tumor microenvironment (TME), we further demonstrate that the combination of CDK4/6 inhibitor abemaciclib and sitravatinib modifies the immune landscape of TNBC to favor immune checkpoint blockade. Overall, our study offers a novel and highly effective combination therapy against TNBC and potentially treatment-resistant HER2+ breast cancer that can be rapidly moved to the clinic.
    Journal
    |
    RB1 (RB Transcriptional Corepressor 1) • AXL (AXL Receptor Tyrosine Kinase) • MERTK (MER Proto-Oncogene, Tyrosine Kinase)
    |
    Verzenio (abemaciclib) • sitravatinib (MGCD516)
    6ms
    SAPPHIRE: Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=577, Active, not recruiting, Mirati Therapeutics Inc. | Trial completion date: Apr 2024 --> Dec 2024
    Trial completion date • Combination therapy • Checkpoint inhibition • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • docetaxel • sitravatinib (MGCD516)
    6ms
    SAFFRON-103: A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=216, Completed, BeiGene | Phase classification: P1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    Tevimbra (tislelizumab-jsgr) • sitravatinib (MGCD516)
    7ms
    Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies (clinicaltrials.gov)
    P1, N=22, Completed, Mirati Therapeutics Inc. | Active, not recruiting --> Completed | N=92 --> 22 | Trial completion date: Feb 2024 --> Jun 2023
    Trial completion • Enrollment change • Trial completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • sitravatinib (MGCD516)
    7ms
    H-43432: Sitravatinib in Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=3, Terminated, Xiang Zhang | Withdrawn --> Terminated; Terminated by sponsor due to lack of interest
    Trial termination • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PTPN12 (Protein Tyrosine Phosphatase Non-Receptor Type 12)
    |
    sitravatinib (MGCD516)
    7ms
    BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
    P3, N=300, Enrolling by invitation, BeiGene | Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Dec 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • Ziihera (zanidatamab-hrii) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • LBL-007 • surzebiclimab (BGB-A425)
    7ms
    National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=423, Active, not recruiting, University of Birmingham | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
    Trial completion date • Trial primary completion date • IO biomarker
    |
    NKX2-1 (NK2 Homeobox 1) • TP63 (Tumor protein 63)
    |
    Xalkori (crizotinib) • Tagrisso (osimertinib) • Ibrance (palbociclib) • Imfinzi (durvalumab) • docetaxel • Koselugo (selumetinib) • Truqap (capivasertib) • fexagratinib (ABSK091) • ceralasertib (AZD6738) • sitravatinib (MGCD516) • vistusertib (AZD2014)
    8ms
    Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study (clinicaltrials.gov)
    P2/3, N=55, Active, not recruiting, Mirati Therapeutics Inc. | Enrolling by invitation --> Active, not recruiting | N=200 --> 55 | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Padcev (enfortumab vedotin-ejfv) • sitravatinib (MGCD516)
    8ms
    Blockade of Discoidin Domain Receptor Signaling with Sitravatinib Reveals DDR2 as a Mediator of Neuroblastoma Pathogenesis and Metastasis. (PubMed, Mol Cancer Ther)
    Analysis of single cell sequencing data demonstrated that DDR2 is restricted to mesenchymal-type tumor subpopulations and is enriched in Schwann Cell Precursor (SCP) subpopulations found in high-risk disease. These data define an unsuspected role for sitravatinib as a therapeutic agent in neuroblastoma and reveal a novel function for DDR2 as a driver of tumor growth and metastasis.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • DDR2 (Discoidin domain receptor 2)
    |
    sitravatinib (MGCD516)
    8ms
    MRTX-500: Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=161, Terminated, Mirati Therapeutics Inc. | Completed --> Terminated; This study was terminated as a result of Sponsor portfolio reprioritization.
    Trial termination • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • sitravatinib (MGCD516) • glesatinib (MGCD265) • mocetinostat (MGCD0103)
    8ms
    BTC-BGB: Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=43, Active, not recruiting, Seoul National University Hospital | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jul 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Tevimbra (tislelizumab-jsgr) • sitravatinib (MGCD516)
    9ms
    H-43432: Sitravatinib in Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, C. Kent Osborne, MD | Terminated --> Withdrawn
    Trial withdrawal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PTPN12 (Protein Tyrosine Phosphatase Non-Receptor Type 12)
    |
    sitravatinib (MGCD516)
    9ms
    SITISVEAL: Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. (clinicaltrials.gov)
    P2, N=16, Active, not recruiting, Grupo Español Multidisciplinar de Melanoma | Recruiting --> Active, not recruiting | N=34 --> 16 | Trial completion date: Aug 2024 --> May 2024
    Enrollment closed • Enrollment change • Trial completion date • Combination therapy • Metastases
    |
    Tevimbra (tislelizumab-jsgr) • sitravatinib (MGCD516)
    10ms
    Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=96, Terminated, BeiGene
    Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
    |
    docetaxel • Tevimbra (tislelizumab-jsgr) • irinotecan • sitravatinib (MGCD516)
    10ms
    BGB-A317-Sitra-301: Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=377, Terminated, BeiGene | Completed --> Terminated; Due to safety risks and unfavorable risk-benefit assessment results, the sponsor has decided to voluntarily terminate the study.
    Trial termination • Combination therapy • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ALK rearrangement
    |
    docetaxel • Tevimbra (tislelizumab-jsgr) • sitravatinib (MGCD516)
    10ms
    Disruption of MerTK increases the efficacy of checkpoint inhibitor by enhancing ferroptosis and immune response in hepatocellular carcinoma. (PubMed, Cell Rep Med)
    Sitravatinib, an inhibitor of MerTK, sensitizes resistant HCC to anti-PD-L1 therapy by promoting tumor ferroptosis and decreasing MDSC infiltration into the TME. In conclusion, we find that MerTK could serve as a predictive biomarker for patient stratification and as a promising target to overcome anti-PD-1/PD-L1 resistance in HCC.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    MERTK (MER Proto-Oncogene, Tyrosine Kinase) • SLC7A11 (Solute Carrier Family 7 Member 11)
    |
    MERTK expression
    |
    sitravatinib (MGCD516)
    10ms
    Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC (clinicaltrials.gov)
    P2, N=9, Terminated, Sarah Goldberg | Trial completion date: Feb 2025 --> Oct 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2025 --> Jun 2023; Sponsor decision based on data from other clinical trials
    Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • sitravatinib (MGCD516)
    11ms
    STELLAR: Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC (clinicaltrials.gov)
    P2, N=5, Terminated, Fudan University | N=36 --> 5 | Recruiting --> Terminated; The trial was terminated per sponsor recommendation
    Enrollment change • Trial termination • Metastases
    |
    Tevimbra (tislelizumab-jsgr) • sitravatinib (MGCD516)
    11ms
    BGB-A317-Sitra-301: Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=377, Completed, BeiGene | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Dec 2023 | Trial primary completion date: Jun 2024 --> Dec 2023
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ALK rearrangement
    |
    docetaxel • Tevimbra (tislelizumab-jsgr) • sitravatinib (MGCD516)
    1year
    A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma. (PubMed, Eur Urol Oncol)
    Sitravatinib plus nivolumab demonstrated a manageable safety profile but did not result in clinically meaningful ORRs in patients with advanced/metastatic UC in the eight cohorts studied.
    P2 data • Journal • Combination therapy • Metastases
    |
    AXL (AXL Receptor Tyrosine Kinase) • KDR (Kinase insert domain receptor) • MERTK (MER Proto-Oncogene, Tyrosine Kinase)
    |
    Opdivo (nivolumab) • sitravatinib (MGCD516)
    1year
    Sitravatinib combined with PD1 blockade enhances cytotoxic T-Cell infiltration by M2 to M1 tumor macrophage repolarization in esophageal adenocarcinoma. (PubMed, Carcinogenesis)
    Additionally, pre-treatment gene expression of TAM receptors and PD-L1 were significantly higher in major responders compared to the non-responders, in animals that received sitravatinib and AUNP-12 (P < 0.02), confirming that TAM suppression enhances the efficacy of PD-1 blockade. In conclusion, this study proposes a promising immunomodulatory strategy using a multi-gene TKI to overcome developed resistance to an ICI in EAC, establishing rationale for future clinical development.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD8 (cluster of differentiation 8) • CASP3 (Caspase 3)
    |
    sitravatinib (MGCD516) • AUNP-12
    1year
    BTC-BGB: Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=43, Active, not recruiting, Seoul National University Hospital | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Dec 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Tevimbra (tislelizumab-jsgr) • sitravatinib (MGCD516)
    1year
    BGB-900-2001-IIT: A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov)
    P2, N=98, Active, not recruiting, Fudan University | Completed --> Active, not recruiting | Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER negative • PGR negative
    |
    Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • sitravatinib (MGCD516)
    1year
    BGB-900-2001-IIT: A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov)
    P2, N=98, Completed, Fudan University | Recruiting --> Completed | Trial primary completion date: Oct 2022 --> Jun 2023
    Trial completion • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER negative • PGR negative
    |
    Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • sitravatinib (MGCD516)
    1year
    A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    docetaxel • Tevimbra (tislelizumab-jsgr) • Cyramza (ramucirumab) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445
    1year
    Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=100, Recruiting, BeiGene | Active, not recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    docetaxel • Tevimbra (tislelizumab-jsgr) • irinotecan • sitravatinib (MGCD516)
    1year
    SAPPHIRE: Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=532, Active, not recruiting, Mirati Therapeutics Inc. | Trial completion date: Jul 2023 --> Apr 2024 | Trial primary completion date: Sep 2022 --> Mar 2023
    Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • docetaxel • sitravatinib (MGCD516)
    1year
    Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies (clinicaltrials.gov)
    P1, N=92, Active, not recruiting, Mirati Therapeutics Inc. | Trial completion date: Jun 2023 --> Feb 2024 | Trial primary completion date: Mar 2023 --> Jun 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • sitravatinib (MGCD516)
    1year
    A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib (clinicaltrials.gov)
    P1, N=30, Completed, Mirati Therapeutics Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    sitravatinib (MGCD516)
    1year
    PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates (clinicaltrials.gov)
    P1, N=40, Completed, Mirati Therapeutics Inc. | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Dec 2022 | Trial primary completion date: Jun 2023 --> Dec 2022
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    Opdivo (nivolumab) • sitravatinib (MGCD516) • midazolam hydrochloride
    1year
    Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    docetaxel • Tevimbra (tislelizumab-jsgr) • irinotecan • sitravatinib (MGCD516)
    1year
    Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=25, Completed, Mirati Therapeutics Inc. | Active, not recruiting --> Completed
    Trial completion • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • CD27 (CD27 Molecule)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • sitravatinib (MGCD516)
    over1year
    Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma. (PubMed, Invest New Drugs)
    Our study also revealed that Sitravatinib effectively inhibited GBM invasive and induced DNA damage and cellular senescence. Furthermore, we observed a novel cell death phenotype induced by Sitravatinib, which differed from previously reported programmed death patterns such as apoptosis, pyroptosis, ferroptosis, and necrosis.
    Journal
    |
    sitravatinib (MGCD516)
    over1year
    SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC) (ESMO 2023)
    Conclusions The primary endpoint of OS was not met in pts with previously treated adv nsq NSCLC. Safety profiles for sitra/nivo and doce were consistent with prior reports for each regimen.
    Clinical • P3 data • Late-breaking abstract • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Opdivo (nivolumab) • docetaxel • sitravatinib (MGCD516)
    over1year
    BGB-900-2003-IIT: A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC (clinicaltrials.gov)
    P2, N=21, Recruiting, Zhejiang Cancer Hospital | N=59 --> 21 | Trial primary completion date: Dec 2024 --> Jul 2023
    Enrollment change • Trial primary completion date
    |
    Tevimbra (tislelizumab-jsgr) • sitravatinib (MGCD516)
    over1year
    ITTACC: Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy (clinicaltrials.gov)
    P2, N=0, Withdrawn, Australia New Zealand Gynaecological Oncology Group | N=57 --> 0 | Trial completion date: Dec 2025 --> Jun 2023 | Initiation date: Mar 2023 --> Jun 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2025 --> Jun 2023
    Enrollment change • Trial completion date • Trial initiation date • Trial withdrawal • Trial primary completion date • Combination therapy • Metastases
    |
    Tevimbra (tislelizumab-jsgr) • sitravatinib (MGCD516)